Aslam Ejaz1, Bradley N Reames1, Shishir Maithel2, George A Poultsides3, Todd W Bauer4, Ryan C Fields5, Matthew J Weiss1, Hugo P Marques6, Luca Aldrighetti7, Timothy M Pawlik8. 1. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA. 2. Department of Surgery, Emory University, Atlanta, GA, USA. 3. Department of Surgery, Stanford University, School of Medicine, Stanford, CA, USA. 4. Department of Surgery, University of Virginia, Charlottesville, VA, USA. 5. Department of Surgery, Washington University, School of Medicine, St Louis, MO, USA. 6. Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal. 7. Department of Surgery, Liver Unit, Scientific Institute San Raffaele, Vita-Salute San Raffaele University, Milan, Italy. 8. Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Abstract
BACKGROUND: Management of neuroendocrine liver metastasis (NELM) in the setting of unresectable disease is poorly defined and the role of debulking remains controversial. The objective of the current study was to define outcomes following non-curative intent liver-directed therapy (debulking) among patients with NELM. METHODS: 612 patients were identified who underwent liver-directed therapy of NELM from a multi-institutional database. Outcomes were stratified according to curative (R0/R1) versus non-curative ≥ 80% debulking (R2). RESULTS: 179 (29.2%) patients had an R2/debulking procedure. Patients undergoing debulking more commonly had more aggressive high-grade tumors (R0/R1: 12.8% vs. R2: 35.0%; P < 0.001) or liver disease burden that was bilateral (R0/R1: 52.8% vs. R2: 75.6%; P < 0.001). After a median follow-up of 51 months, median (R0/R1: not reached vs. R2: 87 months; P < 0.001) and 5-year survival (R0/R1: 85.2% vs. R2: 60.7%; P < 0.001) was higher among patients who underwent an R0/R1 resection compared with patients who underwent a debulking operation. Among patients with ≥50% NELM liver involvement, median and 5-year survival following debulking was 55.4 months and 40.6%, respectively. CONCLUSION: Debulking operations for NELM provided reasonable long-term survival. Hepatic debulking for patients with NELM is a reasonable therapeutic option for patients with grossly unresectable disease that may provide a survival benefit.
BACKGROUND: Management of neuroendocrine liver metastasis (NELM) in the setting of unresectable disease is poorly defined and the role of debulking remains controversial. The objective of the current study was to define outcomes following non-curative intent liver-directed therapy (debulking) among patients with NELM. METHODS: 612 patients were identified who underwent liver-directed therapy of NELM from a multi-institutional database. Outcomes were stratified according to curative (R0/R1) versus non-curative ≥ 80% debulking (R2). RESULTS: 179 (29.2%) patients had an R2/debulking procedure. Patients undergoing debulking more commonly had more aggressive high-grade tumors (R0/R1: 12.8% vs. R2: 35.0%; P < 0.001) or liver disease burden that was bilateral (R0/R1: 52.8% vs. R2: 75.6%; P < 0.001). After a median follow-up of 51 months, median (R0/R1: not reached vs. R2: 87 months; P < 0.001) and 5-year survival (R0/R1: 85.2% vs. R2: 60.7%; P < 0.001) was higher among patients who underwent an R0/R1 resection compared with patients who underwent a debulking operation. Among patients with ≥50% NELM liver involvement, median and 5-year survival following debulking was 55.4 months and 40.6%, respectively. CONCLUSION: Debulking operations for NELM provided reasonable long-term survival. Hepatic debulking for patients with NELM is a reasonable therapeutic option for patients with grossly unresectable disease that may provide a survival benefit.
Authors: Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-01-22 Impact factor: 3.452
Authors: Steven D Scoville; Dimitrios Xourafas; Aslam M Ejaz; Allan Tsung; Timothy Pawlik; Jordan M Cloyd Journal: World J Gastrointest Surg Date: 2020-04-27
Authors: Jonathan G Sham; Aslam Ejaz; Michele M Gage; Fabio Bagante; Bradley N Reames; Shishir Maithel; George A Poultsides; Todd W Bauer; Ryan C Fields; Matthew J Weiss; Hugo Pinto Marques; Luca Aldrighetti; Timothy M Pawlik; Jin He Journal: J Gastrointest Surg Date: 2018-07-06 Impact factor: 3.452
Authors: Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik Journal: Hepatobiliary Surg Nutr Date: 2020-08 Impact factor: 7.293
Authors: Rugved Kulkarni; Irfan Kabir; James Hodson; Syed Raza; Tahir Shah; Sanjay Pandanaboyana; Bobby V M Dasari Journal: Ann Hepatobiliary Pancreat Surg Date: 2022-02-28
Authors: Aileen Xu; Pilar Suz; Tea Reljic; Abhirup C Are; Ambuj Kumar; Benjamin Powers; Jonathan Strosberg; Jason W Denbo; Jason B Fleming; Daniel A Anaya Journal: Cancers (Basel) Date: 2022-06-16 Impact factor: 6.575